REGN Regeneron Pharmaceuticals

Q2 2025 10-Q

Filed: Aug 1, 2025Period ending Jun 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Regeneron Pharmaceuticals (REGN) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 1, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Risk Factors

• New risk: EYLEA U.S. net product sales declined 39% YoY Q2 2025 due to intensified competition impacting near-term revenue
• Updated commercialization risk: Increased dependence on EYLEA HD as it represented 32% of aggregate EYLEA U.S. sales H1 2025 vs 44% total EYLEA sales H1 2024

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$3.7B

▲ +3.6% YoY▲ +21.4% QoQ

Net Income

$1.4B

▼ -2.8% YoY▲ +72.1% QoQ

Net Margin

37.9%

▼ -252bp YoY▲ +1116bp QoQ

Source: XBRL data from Regeneron Pharmaceuticals Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Regeneron Pharmaceuticals Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Regeneron Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.